claim: evaluation of two commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay
evidence_1: conclusions thorough on-site evaluation of commercially available serologic tests for detection of antibodies against sars-cov-2 remains imperative for laboratories.", "the potentially impaired sensitivity of the siemens cov2g necessitates a switch to the companys newly filed sars-cov-2 igg assay (scovg) for follow-up studies.", "roc curve analyses suggest a lowering of the cut-off index for the siemens cov2g assay.", "finally, the combination of two anti-sars-cov-2 antibody assays is feasible when considering borderline reactive results."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )